Position statements and endorsement letters are essential for expressing the CNS’s stance on key issues in child neurology, guiding decisions, and advocating efforts.
Position statements are developed through expert consensus, drawing on the best available evidence. Crafted by CNS committees, they undergo a thorough review and Board approval.
Endorsement and sign-on letters allow the CNS to support important initiatives. These letters are collaboratively developed with expert input and aligned organizations, ensuring they reflect CNS priorities before final Board approval.
Position Statements
Universal Interview Offer Date
The Child Neurology Society (CNS) strongly recommends that Child Neurology and Neurodevelopmental Disabilities residency programs adopt a universal interview offer date of October 10, 2024.
Endorsed by the CNS
Guideline Endorsement: American Academy of Neurology
Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication
This practice guideline provides updated evidence-based conclusions and recommendations regarding the effects of antiseizure medications and folic acid supplementation on the prevalence of major congenital malformations, adverse perinatal outcomes, and neurodevelopmental outcomes in children born to people with epilepsy of childbearing potential.
Consensus Guideline: Codeveloped with the American Academy of Neurology, American Academy of Pediatrics, and the Society of Critical Care Medicine
Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Practice Guideline
This guideline provides recommendations on the evaluation of brain death/death by neurologic criteria for both children and adults. The recommendations cover (1) general principles for the BD/DNC evaluation, (2) qualifications to perform BD/DNC evaluations, (3) prerequisites for BD/DNC determination, (4) components of the BD/DNC neurologic examination, (5) apnea testing as part of the BD/DNC evaluation, (6) ancillary testing as part of the BD/DNC evaluation, and (7) special considerations for BD/DNC determination.
Policy Endorsement: Coalition Support
H.R.6664 – Innovation in Pediatric Drugs Act of 2023
On behalf of the undersigned organizations, we write to offer our strong support for your legislation, the Innovation in Pediatric Drugs Act of 2023 (H.R. 6664). Children are not just small adults. Drugs work differently in children and adolescents and must be studied specifically for their use. Yet too often, drug development leaves children behind. H.R. 6664 will help speed therapies to the children and adolescents who need them–including children with rare diseases–by making needed changes to the pediatric drug laws.
Policy Endorsement: Coalition Support
Pediatric Subspecialty Loan Repayment Program (PSLRP)
Our organizations write to you today about the implementation of the Pediatric Subspecialty Loan Repayment Program (PSLRP). We greatly appreciate the work of the Health Resources and Services Administration (HRSA) to issue the first-ever PSLRP awards last year, and to work with provider organizations to address some of the challenges that applicants faced with last year’s application process. As you know, this important program was created to address the serious shortages of pediatric medical subspecialists, pediatric surgical specialists, and pediatric mental health providers across the United States, which directly impact access to equitable care for children, especially those with serious, chronic or complex health care needs.
Apply to the Pediatric Specialty Loan Repayment Program